COGT Earnings Cogent Biosciences, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–29 of 29
| Q2 2026 | 2026-06-30 | -1.05 | 2026-08-10 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.53 | 2026-05-05 | 10-Q |
| FY 2025 | 2025-12-31 | -2.16 | 2026-02-17 | 10-K |
| Q3 2025 | 2025-09-30 | -1.55 | 2025-11-07 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.05 | 2026-08-10 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.52 | 2026-05-05 | 10-Q |
| FY 2025 | 2024-12-31 | -1.94 | 2026-02-17 | 10-K |
| Q3 2025 | 2024-09-30 | -1.44 | 2025-11-07 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.91 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.49 | 2025-05-06 | 10-Q |
| FY 2025 | 2023-12-31 | -1.94 | 2026-02-17 | 10-K |
| Q3 2024 | 2023-09-30 | -1.79 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.14 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.55 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -1.73 | 2025-02-25 | 10-K |
| Q3 2023 | 2022-09-30 | -1.84 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.39 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.68 | 2023-05-09 | 10-Q |
| FY 2023 | 2021-12-31 | -1.87 | 2024-02-26 | 10-K |
| Q3 2022 | 2021-09-30 | -1.25 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.77 | 2022-08-09 | 10-Q |
| FY 2019 | 2019-12-31 | 0.07 | 2020-03-26 | 10-K |
| FY 2019 | 2019-09-30 | -0.39 | 2020-03-26 | 10-K |
| FY 2019 | 2019-06-30 | -0.34 | 2020-03-26 | 10-K |
| FY 2019 | 2019-03-31 | -0.39 | 2020-03-26 | 10-K |
| FY 2019 | 2018-12-31 | -0.29 | 2020-03-26 | 10-K |
| FY 2019 | 2018-09-30 | -0.34 | 2020-03-26 | 10-K |
| FY 2019 | 2018-06-30 | -0.31 | 2020-03-26 | 10-K |
| FY 2019 | 2018-03-31 | -0.66 | 2020-03-26 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.